These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 33550776)

  • 21. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.
    Noor R
    Curr Clin Microbiol Rep; 2021; 8(3):178-185. PubMed ID: 33686365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.
    Ophinni Y; Hasibuan AS; Widhani A; Maria S; Koesnoe S; Yunihastuti E; Karjadi TH; Rengganis I; Djauzi S
    Acta Med Indones; 2020 Oct; 52(4):388-412. PubMed ID: 33377885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination.
    Hsieh MH; Yamaguchi Y
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
    Sønderskov KM; Dinesen PT; Østergaard SD
    Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
    Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
    Marsh GA; McAuley AJ; Au GG; Riddell S; Layton D; Singanallur NB; Layton R; Payne J; Durr PA; Bender H; Barr JA; Bingham J; Boyd V; Brown S; Bruce MP; Burkett K; Eastwood T; Edwards S; Gough T; Halpin K; Harper J; Holmes C; Horman WSJ; van Vuren PJ; Lowther S; Maynard K; McAuley KD; Neave MJ; Poole T; Rootes C; Rowe B; Soldani E; Stevens V; Stewart CR; Suen WW; Tachedjian M; Todd S; Trinidad L; Walter D; Watson N; Drew TW; Gilbert SC; Lambe T; Vasan SS
    NPJ Vaccines; 2021 May; 6(1):67. PubMed ID: 33972565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges.
    Rahman MM; Masum MHU; Wajed S; Talukder A
    Virusdisease; 2022 Mar; 33(1):1-22. PubMed ID: 35127995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-Reactivity between Half Doses of Pfizer and AstraZeneca Vaccines-A Preliminary Study.
    Lukaszuk K; Podolak A; Malinowska P; Lukaszuk J; Jakiel G
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.
    Ferretti F; Cannatelli R; Benucci M; Carmagnola S; Clementi E; Danelli P; Dilillo D; Fiorina P; Galli M; Gallieni M; Genovese G; Giorgi V; Invernizzi A; Maconi G; Maier JA; Marzano AV; Morpurgo PS; Nebuloni M; Radovanovic D; Riva A; Rizzardini G; Sabiu G; Santus P; Staurenghi G; Zuccotti G; Sarzi-Puttini PC; Ardizzone S
    Front Immunol; 2021; 12():656362. PubMed ID: 33936084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021.
    Moline HL; Whitaker M; Deng L; Rhodes JC; Milucky J; Pham H; Patel K; Anglin O; Reingold A; Chai SJ; Alden NB; Kawasaki B; Meek J; Yousey-Hindes K; Anderson EJ; Farley MM; Ryan PA; Kim S; Nunez VT; Como-Sabetti K; Lynfield R; Sosin DM; McMullen C; Muse A; Barney G; Bennett NM; Bushey S; Shiltz J; Sutton M; Abdullah N; Talbot HK; Schaffner W; Chatelain R; Ortega J; Murthy BP; Zell E; Schrag SJ; Taylor C; Shang N; Verani JR; Havers FP
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1088-1093. PubMed ID: 34383730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines.
    Vallée A; Vasse M; Mazaux L; Bonan B; Amiel C; Zia-Chahabi S; Chan-Hew-Wai A; Farfour E; Camps E; Touche P; Barret F; Parquin F; Zucman D; Fourn E
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review.
    Sarkar M; Madabhavi IV; Quy PN; Govindagoudar MB
    Ann Thorac Med; 2022; 17(1):1-13. PubMed ID: 35198043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis.
    Jahn M; Korth J; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Tyczynski B; Gäckler A; Witzke O; Dittmer U; Dolff S; Wilde B; Kribben A
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33918085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview.
    Shiravi AA; Ardekani A; Sheikhbahaei E; Heshmat-Ghahdarijani K
    Cardiol Ther; 2022 Mar; 11(1):13-21. PubMed ID: 34845662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19].
    Wolthers SA; Stenberg J; Nielsen HB; Stensballe J; Pedersen HP
    Ugeskr Laeger; 2021 Aug; 183(35):. PubMed ID: 34477089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review the safety of Covid-19 mRNA vaccines: a review.
    Anand P; Stahel VP
    Patient Saf Surg; 2021 May; 15(1):20. PubMed ID: 33933145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population.
    Guzmán-Martínez O; Guardado K; de Guevara EL; Navarro S; Hernández C; Zenteno-Cuevas R; Montero H
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erratum to: Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections. Med Sci Monit. 2021;27:e932899, doi: 10.12659/MSM.932899.
    Parums DV
    Med Sci Monit; 2021 May; 27():e932986. PubMed ID: 33947822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases].
    Indolfi C; Barillà F; Basso C; Ciccone MM; Curcio A; Mancone M; Mercuro G; Muscoli S; Nodari S; Pedrinelli R; Romeo F; Sinagra G; Filardi PP
    G Ital Cardiol (Rome); 2021 May; 22(5):363-375. PubMed ID: 33960979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.